The best methods of preventing infection and complications from central lines will be investigated in a new clinical trial.
Led by The University of Queensland, the IVCare trial will examine central venous access devices (CVADs) that are commonly used in cancer treatment, dialysis and intensive care.
Professor Claire Rickard , of UQ's School of Nursing, Midwifery and Social Work , said CVADs allow medicines and fluids to be given directly into the bloodstream, and blood to be withdrawn for dialysis or blood tests.
"These devices are a type of intravenous (IV) line used by more than 100,000 Australians each year, but complications such as bloodstream infections, catheter dislodgement and blood clots can interrupt therapy, prolong hospitalisation and increase healthcare costs and mortality risk,'' Professor Rickard said.
"Currently, decisions about CVAD products and practices can be influenced by what is available or familiar at an individual hospital.
"We need stronger comparative evidence so that these decisions can be based on what is most likely to benefit patients.
"People living with CVADs depend on these devices for essential treatment, both in hospital and at home, sometimes for months or even years.
"Preventing complications can make a real difference to their treatment, health and quality of life.''
The IVCare trial uses a new approach called a platform trial which allows many trials to be completed within the same study.
It will examine all CVAD types - PICCs inserted into the arm, port devices placed under the skin, and dialysis or other central lines inserted into the neck, chest or groin - at 20 hospitals across Australia, with plans to expand internationally.
The trial will allow researchers to test several interventions at the same time and compare different strategies.
Testing will examine products used to prevent infections and complications including skin antiseptics, dressings and fasteners, device cleaning protocols, antimicrobial solutions, as well as different CVAD designs.
Professor Rickard said the trial results would inform future clinical guidelines.
"There is no one-size-fits-all approach to vascular access care,'' she said.
"What works well for one patient group may not be the best option for another, which is why it is important to evaluate these interventions across different patients who rely on CVADs.
"There is already some evidence on the effectiveness of individual interventions, but we need stronger evidence to be certain, as well as to be flexible and ready to compare new products as these come along.
"This trial is only possible because of the strong partnerships we have with partner researchers, consumers and hospitals who are all committed to better, safer care.''
Visit the website for more information on the IV Care trial .
Collaborations and acknowledgements:
The trial will be conducted in association with UQ's Frazer Institute .
